Patents by Inventor William Kubasek
William Kubasek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10273304Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In oth6er aspects the biomarkers are proteins and/or nucleic acids.Type: GrantFiled: May 22, 2017Date of Patent: April 30, 2019Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Bambang Adiwijaya, Akos Czibere, William Kubasek, Gavin MacBeath, Sharon Moulis, Rachel C. Nering, Lin Nie, Defne Yarar
-
Publication number: 20170307631Abstract: The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.Type: ApplicationFiled: December 20, 2016Publication date: October 26, 2017Inventors: Birgit SCHOEBERL, Brian HARMS, Francis David GIBBONS, Jonathan Basil FITZGERALD, Matthew David ONSUM, Ulrik NIELSEN, William KUBASEK
-
Publication number: 20170267767Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids.Type: ApplicationFiled: May 22, 2017Publication date: September 21, 2017Applicants: Merrimack Pharmaceuticals, Inc., Merrimack Pharmaceuticals, Inc.Inventors: Bambang ADIWIJAYA, Akos CZIBERE, William KUBASEK, Gavin MACBEATH, Sharon MOULIS, Rachel C. NERING, Lin NIE, Defne YARAR
-
Publication number: 20170210810Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids.Type: ApplicationFiled: December 21, 2016Publication date: July 27, 2017Inventors: Bambang ADIWIJAYA, Akos CZIBERE, William KUBASEK, Gavin MACBEATH, Sharon MOULIS, Rachel C. NERING, Lin NIE, Defne YARAR
-
Patent number: 9688761Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids.Type: GrantFiled: December 10, 2015Date of Patent: June 27, 2017Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Bambang Adiwijaya, Akos Czibere, William Kubasek, Gavin MacBeath, Sharon Moulis, Rachel C. Nering, Lin Nie, Defne Yarar
-
Publication number: 20160090418Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids.Type: ApplicationFiled: December 10, 2015Publication date: March 31, 2016Inventors: Bambang ADIWIJAYA, Akos CZIBERE, William KUBASEK, Gavin MACBEATH, Sharon MOULIS, Rachel C. NERING, Lin NIE, Defne YARAR
-
Publication number: 20150231238Abstract: Provided are methods for overcoming resistance to an ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor. The resistance may be acquired resistance to an EGFR inhibitor, such as acquired resistance to gefitinib. In the methods provided, a subject exhibiting resistance to an ErbB pathway inhibitor is selected and both an ErbB 3 inhibitor and a second ErbB pathway inhibitor are administered to the subject, such as an EGFR inhibitor or a HER2 inhibitor. Also provided are methods for inhibiting the growth of a tumor comprising a T790M EGFR mutation by contacting the tumor with an ErbB3 inhibitor and an EGFR inhibitor. Compositions for overcoming resistance to an ErbB pathway inhibitor, comprising both an ErbB 3 inhibitor and a second ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor, are also provided.Type: ApplicationFiled: March 15, 2012Publication date: August 20, 2015Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Gabriela Garcia, William Kubasek, Maria Johanna Lahdenranta, Gavin MacBeath, Charlotte McDonagh, Victor Moyo, Matthew David Onsum, Birgit Schoeberl, Mark Sevecka, Marisa Wainszelbaum, Bo Zhang
-
Publication number: 20140248280Abstract: Provided are methods and compositions for clinical treatment of advanced gynecological cancers using anti-ErbB3 antibodies combined with paclitaxel.Type: ApplicationFiled: June 13, 2012Publication date: September 4, 2014Applicants: SANOFI, MERRIMACK PHARMACEUTICALS, INC.Inventors: William Kubasek, Victor Moyo, Joseph Pearlberg, Isabelle Tabah-Fisch, Gavin MacBeath
-
Publication number: 20140234317Abstract: Methods are disclosed for preventing toxic drug-drug interactions during combination cancer therapy with a drug that is an anti-ErbB3 agent, such as an anti-ErbB3 antibody, together with a drug that is a tyrosine kinase inhibitor and/or a drug that binds to alpha-1 acid glycoprotein (e.g., erlotinib). Health care practitioners obtaining any one of the drugs are warned that when co-administering the drug that is an anti-ErbB3 agent with either or both of a drug that is a tyrosine kinase inhibitor and a drug that binds to alpha-1 acid glycoprotein, at least one of the co-administered drugs should be administered using a reduced dosage to prevent toxicity. In a reduced dosage, the amount of drug administered per unit time is reduced as compared to a dose that would be administered if the drug was administered as monotherapy. The reduced dosage can be, for example, a reduced drug dose or a reduced drug dosing frequency, or both. Compositions useful in practicing the disclosed methods are also provided.Type: ApplicationFiled: May 4, 2012Publication date: August 21, 2014Applicant: Merrimack Pharmaceuticals, Inc.Inventors: Matthew David Onsum, Clet Niyikiza, Victor Moyo, William Kubasek, Akos Czibere
-
Publication number: 20140134170Abstract: Provided are methods of suppressing growth of hormone refractory breast tumors by contacting tumor cells with an ErbB3 inhibitor, preferably an anti-ErbB3 antibody. Also provided are methods for treating hormone refractory breast cancer in a patient by administering to the patient an inhibitor of heregulin binding to ErbB3 or to ErbB2/ErbB3 heterodimer, which inhibitor is an anti-ErbB3 antibody or an anti-ErbB2 antibody. The treatment methods can further comprise selecting a patient having a hormone refractory breast cancer and then administering the inhibitor to the patient. The treatment methods may also comprise administering an estrogen receptor antagonist, or an aromatase inhibitor to the patent and may at further comprise administering to the patient at least one additional anti-cancer agent that is not an ErbB3 inhibitor, an estrogen receptor antagonist, or an aromatase inhibitor to the patient in combination with the ErbB3 inhibitor.Type: ApplicationFiled: March 12, 2012Publication date: May 15, 2014Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Gabriela Garcia, William Kubasek, Gavin Macbeath, Victor Moyo
-
Publication number: 20140127238Abstract: The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.Type: ApplicationFiled: January 6, 2014Publication date: May 8, 2014Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Birgit SCHOEBERL, Brian HARMS, Francis David GIBBONS, Jonathan Basil FITZGERALD, Matthew David ONSUM, Ulrik NIELSEN, William KUBASEK
-
Patent number: 8623592Abstract: The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted124 based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.Type: GrantFiled: August 17, 2009Date of Patent: January 7, 2014Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Birgit Schoeberl, Brian Harms, Francis David Gibbons, Jonathan Basil Fitzgerald, Matthew David Onsum, Ulrik Nielsen, William Kubasek
-
Publication number: 20110159513Abstract: The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.Type: ApplicationFiled: August 17, 2009Publication date: June 30, 2011Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Birgit Schoeberl, Brian Harms, Francis David Gibbons, Jonathan Basil Fitzgerald, Matthew David Onsum, Ulrik Nielsen, William Kubasek
-
Publication number: 20110027291Abstract: The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.Type: ApplicationFiled: February 17, 2010Publication date: February 3, 2011Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Birgit SCHOEBERL, Brian HARMS, Francis David GIBBONS, Jonathan Basil FITZGERALD, Matthew David ONSUM, Ulrik NIELSEN, William KUBASEK
-
Patent number: 5854204Abstract: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural .beta. amyloid peptides (.beta.-AP). In a preferred embodiment, the .beta. amyloid modulator compounds of the invention are comprised of an A.beta. aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural .beta. amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural .beta.-AP aggregation when the natural .beta.-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.Type: GrantFiled: March 14, 1996Date of Patent: December 29, 1998Assignee: Praecis Pharmaceuticals, Inc.Inventors: Mark A. Findeis, Howard Benjamin, Marc B. Garnick, Malcolm L. Gefter, Arvind Hundal, Laura Kasman, Gary Musso, Ethan R. Signer, James Wakefield, Michael Reed, Susan Molineaux, William Kubasek, Joseph Chin, Jung-Ja Lee, Michael Kelley